Bone Void Fillers Market Size Analysis

The Bone Void Fillers Market size was valued at USD 3.56 billion in 2024 and is expected to reach USD 6.00 billion by 2032 and grow at a CAGR of 6.76% over the forecast period of 2025-2032.

The bone void fillers market is undergoing substantial change due to the rising prevalence of orthopedic disorders, trauma, osteoporotic fractures, and spinal and tumor-related bone defects. Globally, the number of fragility fractures from osteoporosis is projected to increase dramatically, with more than 8.9 million people suffering such fractures each year, the International Osteoporosis Foundation reports. With the increase in bone fractures, there has been an increase in the usage of artificial, allograft, and xenograft bone substitutes.

Favorable access to high-end biomaterials, along with an increasing elderly population, will boost the bone void fillers market globally. In the U. S. bone void filler market, however, spinal surgeries take place every 8 minutes, and many of these entail vertebral augmentation in which the fillers are necessary, according to Pain News Network. There is an increasing load of musculoskeletal problems and revision operations. In addition, developments in calcium phosphate and hydrogel-based biomaterials have improved the integration and healing, significantly fueling the growth of the bone void fillers market. Major factors driving the rise in demand are growing sports-related injuries and increasing post-tumor resection void management.

Increasing government backing and research and development (R&D) investments are equally driving the bone void fillers market. The U.S. FDA provided special Class II guidance for resorbable calcium salt bone void filler devices to ease regulatory pathways and safety measures. The agency said these special controls have facilitated faster innovation and broader use.

Anika Therapeutics and others are gaining additional 510(k) clearance for their Tactoset injectable bone substitute, expanding indications for use and increasing the share of the bone void fillers market. Additionally, Elute was granted clearance by the FDA for its new synthetic resorptive filler with locally sourced antibiotic release, demonstrating innovation in drug-device combinations. Orthofix and MTF Biologics' partnership reinforces the trend of strategic alliances to expand supply and access to advanced allograft products and enhance the supply chain across the world in the bone void fillers market.

In April 2024, Anika's bone void fillers market penetration was extended with a new FDA 510(k) clearance for Tactoset, a product designed for use in multiple orthopedic procedures.

On the investment side, Sanara MedTech’s 2025 transaction with Biomimetic Innovations Ltd. underscores investor appetite for synthetic biomaterials. Such collaborations indicate prospective initiatives toward bone void fillers market analysis due to the fact that it requires biocompatibility and bioactivity. There is a growing R&D on polymer-ceramic hybrid materials and 3D-printed scaffolds with improved resorption and mechanical properties. ACSBiomaterials Metadata collected evidence that composites with alginate, gelatin, and hydroxyapatite greatly improve osteoinductivity. The companies that make bone void fillers have products in the pipeline that are multifunctional fillers that provide structural support and local drug delivery, and increased osteogenesis.

In January 2025, Biomimetic Innovations Ltd. reached a licensing and investment deal with Sanara MedTech Inc. to accelerate the commercialization of innovative biomimetic void filler products.

Bone Void Fillers Market Dynamics

Drivers:

• Increasing Bone Disorders, Surgical Demand, and Innovation in Biomaterials Drive Market Expansion

Bone void fillers market expansion is driven by increasing incidences of bone diseases and prevalence of orthopedic and trauma surgeries globally. Aggressive marketing strategies by major players, such as new product launches and activities including mergers & acquisitions, are expected to intensify the competition among the players operating in the market. More than 2.8 million bone grafts are done every year globally, and the tendency is an increase in the usage of synthetic grafts, because of drawbacks to autografts and allografts. Enhanced demand is also generated by the development of new biomaterials technologies, such as biphasic calcium phosphate ceramics and polymer and composites, which mirror natural bone remodeling.

Moreover, the development of injectable and moldable formulations is also facilitating minimally invasive surgical procedures. There is also an apparent increase in the investment in orthopedic biomaterials. The European Union’s Horizon 2020 program has earmarked over USD 54.25 million for innovations within regenerative medicine and bone repair. Inflammatory Response The modulatory capacity of bone substitutes relates in part to the dynamics of regulation and the role that regulatory facilitation plays, such as the FDA’s efficient 510(k) clearance process for new bone substitutes encourages availability, creatively stimulating both supply and innovation. Institutional adoption is also being pushed by defense and sports injury-related procedures.

Restraints:

• Risk of Infection, Product Failure, and Regulatory Complexities Limit Broader Adoption

The bone void fillers market growth is hindered by post-implantation clinical adversities, such as tissue graft rejection, chronic inflammation, or infection. The incidence of delayed healing or complications in synthetic bone graft surgery is reported to be approximately 8%–15 %, with higher rates in those with immunodeficiency or systemic diseases, etc. Reduced inductive activity of some synthetic fillers also limits effectiveness, particularly in load-bearing situations.

Regulatory hurdles compound the problem, and in a number of areas, tough clinical validation of Class II biomaterials may delay market access and hike R&D costs. The FDA provides guidelines, but there is no global standardization, which makes it challenging for bone void filler companies to expand internationally. Moreover, variation in filler porosity and resorption rates due to differences in manufacturing affects product quality and is a source of inaccuracy in clinical results. Market penetration is inhibited due to the high cost of high-end resin and biocompatibility, and some healthcare systems do not reimburse, especially in low-income settings, limiting supply and access.

Bone Void Fillers Market Segmentation Overview

By Type

The demineralized bone matrix segment dominated the market for bone void fillers in 2024, with a revenue share of around 34.2% of the overall market. It is the most prevalent DBM due to its high level of osteoinduction, availability in many forms, and common usage in spinal and orthopedic surgery. The calcium sulfate segment is expected to witness the highest CAGR during the forecast period (2025-2032) due to the growing focus on complete resorbability, ease of use, and low risk of infection associated with the material. Due to its bioabsorbable property and applicability in minimally invasive surgery, it has been widely used in trauma and dental systems.

By Form

The putty segment held the largest share in the global bone void fillers market in 2024, and it is also expected to witness the fastest growth during 2025-2032, among all the types, owing to its better handling characteristics, capability to adapt to the irregular defects, and its increased adoption in the surgeries. It is also easier to insert into difficult anatomic locations. Paste is expected to register the highest CAGR during 2025-2032. Its fast-curing nature, low invasiveness, and increased usability in arthroscopic and endoscopic procedures are accelerating its use in various types of surgeries.

By End-user

Hospitals were the major end-user in the bone void fillers market in 2024, with a share of 48.5%. The high number of patients, availability of state-of-the-art facilities, and better accessibility to bone graft materials might have led to dominance of this segment. By contrast, specialty clinics are anticipated to post the fastest gains in demand over the forecast period as they expand their role in ambulatory orthopedic procedures, strengthen investments in specialty care, and aging populations preferentially opt for minimally invasive bone repair methods.

Bone Void Fillers Market Regional Outlook

North America dominated the overall bone void fillers industry in 2024 due to a higher number of orthopedic procedures, a favorable reimbursement scenario, and a strong presence of key players in this region.

The U.S. bone void fillers market size was valued at USD 1.16 billion in 2024 and is expected to reach USD 1.83 billion by 2032, growing at a CAGR of 5.92% over the forecast period of 2025-2032. The regional market was led by the U.S. owing to the rising number of spinal fusions and trauma surgeries, and more than 1.62 million orthopedic surgeries are conducted each year in the U.S. Furthermore, positive reimbursement scenarios and fast approvals from the FDA of novel bone graft substitutes are aiding adoption.

The growing aged population and increasing use of synthetic fillers in outpatient orthopedic procedures in the country are also expected to be major factors in fueling demand for the market in Canada. Mexico is being born with new public health facilities and orthopedic technology available. The area is fueled by heavy spending on R&D, clinical trials, and strategic partnerships between industry and health care organizations.

The European market for bone void fillers is the second fastest-growing within the bone void fillers market due to the growing prevalence of osteoporosis, musculoskeletal disorders geriatric population. More than 22 million women and 5.5 million men suffer from osteoporosis in the EU, driving surgical treatments. Germany leads the European market because of large surgical volumes and robust orthopedic infrastructure, along with the presence of local manufacturers and insurance coverage in the country.

France and the U.K., too, are growing significantly with increased investments in bioactive scaffolds and regenerative orthopedics. Government-sponsored initiatives and public-private R&D programs are propelling the development of calcium phosphate and composite fillers. Popularization of sustainable, biocompatible Europe’s preference for sustainable, biocompatible materials, and strict yet harmonized CE regulatory standards will contribute to faster adoption and robust regional supply chains.

The Asia Pacific is the fastest-growing region in the bone void fillers market due to the increasing number of surgeries, geriatric population, and the increasing number of trauma and cancer-induced orthopedic surgeries. China is the largest regional market, buoyed by an increase in the number of spinal and hip fracture surgeries, more than 1 million hip fractures per year, and strong domestic production of biomaterials.

The government’s “Made in China 2025” strategy also encourages the development of domestic biomaterials. India is growing at a fast pace on account of rising incidences of healthcare due to better access to healthcare, rising road accidents, and growth in synthetic bone graft technology. In minimally invasive orthopedics, Japan, with its aging population and superior biotech research, remains a space for innovation. Furthermore, nations such as South Korea and Australia have an increasing demand as a result of active surgical programs and favorable regulatory access pathways.

Key Players in the Bone Void Fillers Market

Leading bone void fillers companies operating in the market include BONESUPPORT AB, Biocomposites, Collagen Matrix, Inc., Zimmer Biomet, Stryker, Arthrex, Inc., DePuy Synthes, Graftys, Kuros Biosciences, and Baxter International.

Recent Developments in the Bone Void Fillers Market

In January 2025, LifeNet Health introduced PliaFX Flo, a next-generation addition to its PliaFX portfolio of advanced fiber demineralized bone matrices. This innovative bone void solution, now available in a pre-filled syringe format, is engineered to amplify healing potential, delivering greater confidence to surgeons and better outcomes for patients.

In November 2024, Acuitive Technologies announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market CITREPORE, a unique synthetic bioactive bone void filler. CITREPORE utilizes the company's patented CITREGEN biomaterial technology, which is resorbed predictably and replaced by the patient’s bone, providing citrate to guide the healing process metabolically.